SCHEMBL3013569

SCHEMBL3013569

Cc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4cccc(F)c4)CC3)n2)c1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
USP2 O75604 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
ALDH1A1 P00352 5/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
RAB9A P51151 1/20 0.46
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
TSHR P16473 3/20 0.44
LMNA P02545 3/20 0.44
HTT P42858 2/20 0.44
GAA P10253 2/20 0.44
POLB P06746 1/20 0.44
MAPK1 P28482 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
GFER P55789 1/20 0.44
GBA1 P04062 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016995 0.94 KMT2A (0.47) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3019967 0.91 ALDH1A1 (0.59) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3023011 0.90 RAB9A (0.48) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3016087 0.89 LMNA (0.47) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3008951 0.89 GBA1 (0.43) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3010517 0.88 TSHR (0.49) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL2998720 0.88 POLB (0.53) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3011989 0.88 ALDH1A1 (0.47) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3010117 0.88 LMNA (0.45) MAPTUSP2RECQLHSD17B10ALDH1A1
SCHEMBL3013261 0.87 ALDH1A1 (0.47) MAPTUSP2RECQLHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.